Integer (NYSE:ITGR – Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share guidance of 5.010-5.430 for the period, compared to the consensus earnings per share estimate of 5.310. The company issued revenue guidance of $1.7 billion-$1.8 billion, compared to the consensus revenue estimate of $1.8 billion. Integer also updated its FY24 guidance to $5.01-5.43 EPS.
Integer Price Performance
Shares of Integer stock traded down $10.41 on Thursday, hitting $112.86. The company’s stock had a trading volume of 342,010 shares, compared to its average volume of 322,735. Integer has a 52-week low of $69.40 and a 52-week high of $123.99. The company has a quick ratio of 1.71, a current ratio of 2.80 and a debt-to-equity ratio of 0.64. The firm has a fifty day moving average price of $112.68 and a 200-day moving average price of $99.49. The company has a market capitalization of $3.78 billion, a P/E ratio of 42.00, a price-to-earnings-growth ratio of 1.63 and a beta of 1.10.
Integer (NYSE:ITGR – Get Free Report) last released its earnings results on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.05. Integer had a net margin of 5.68% and a return on equity of 10.80%. The company had revenue of $413.15 million for the quarter, compared to analyst estimates of $409.04 million. During the same period in the prior year, the firm earned $1.11 EPS. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. On average, equities research analysts expect that Integer will post 5.31 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on Integer
About Integer
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
Further Reading
- Five stocks we like better than Integer
- Investing in Construction Stocks
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- 5 Top Rated Dividend Stocks to Consider
- Power Surge: Utilities Sector’s Resilience Shines
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Bargain Stocks Near 52-week Lows
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.